Sign in
Taking people in United StatesPhase 2

Tests timing of ipilimumab and nivolumab in advanced melanoma

Tests morning versus other-time-of-day dosing of two immunotherapy drugs in advanced melanoma.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the 2 sites
Trial code
Registry title
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Status
Recruiting
Phase
Phase 2
People taking part
99 people, planned
Started
29 Oct 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Biopsy Procedure
  • Biospecimen Collection
  • Computed Tomography
  • Ipilimumab
  • Magnetic Resonance Imaging
  • Medical Device Usage and Evaluation
  • Nivolumab
  • Questionnaire Administration
Record updated
12 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage IV melanoma of the skin, palms/soles or mucous membranes that cannot be removed by surgery. It tests giving ipilimumab and nivolumab in the morning versus other times of day.

Age
18 years or older
Sex
All sexes can join
Disease stage
Stage IV melanoma (AJCC 8th edition) that cannot be removed by surgery: cutaneous, acral or mucosal. Not uveal melanoma. Brain metastases under 2 cm (0.8 in) without symptoms or bleeding are allowed.
Earlier treatment
No immunotherapy within the last 1 year. BRAF/MEK inhibitors are allowed.

Main reasons for not taking part

  • Taking more than 10mg prednisone daily
  • Active autoimmune disease that would prevent immunotherapy
  • Active leptomeningeal disease
  • Uveal melanoma
  • ECOG score above 1

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Pathologically confirmed American Joint Committee on Cancer (AJCC) 8th edition stage IV unresectable cutaneous, acral, or mucosal melanoma
  • No uveal melanoma
  • Patients with asymptomatic, non-hemorrhagic brain metastases < 2 cm are eligible
  • No prior immunotherapy within 1 year, (serine/threonine-protein kinase B-raf [BRAF]/mitogen-activated protein kinase [MEK] inhibitors allowed)
  • Eastern Cooperative Oncology Group (ECOG) 0-1
  • Age ≥ 18
  • Adequate organ function to receive ipilimumab/nivolumab

Who cannot take part

  • Active autoimmune disease that would preclude the administration of immunotherapy
  • Active leptomeningeal disease
  • Immunosuppression (> 10mg prednisone daily)

Where in United States

  • Emory Saint Joseph's HospitalAtlanta, United StatesContact: Tiffaney RoundtreeNot yet recruiting
  • Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Tiffaney RoundtreeTaking people

About the trial

What the trial wants to find out

This phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients with melanoma that is stage IV or that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. While some patients have impressive outcomes with both of these drugs, over 40% of patients do not experience any clinical benefit. Studies have shown that the time of day that vaccines and other therapies are given have had an impact on response and survival. It is not known, however, whether time of day has an impact on response to immune checkpoint inhibitors, such as ipilimumab and nivolumab. Giving ipilimumab and nivolumab earlier in the day compared to later in the day may improve response to treatment and survival in patients with stage IV or unresectable melanoma.

The 3 groups in the trial

  • Arm I (nivolumab, ipilimumab)Treatment being tested

    Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes at 0800-1100 on day 1 of each cycle. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance nivolumab for up to a total of 2 years. Patients wear an actigraphy device for 5-7 days at enrollment prior to first infusion and for up to 4 weeks then over 3 weeks starting with visit 4. Patients also undergo check swab and blood sample collection, CT or MRI and MRI or CT of brain throughout the study. Additionally, patients may optionally undergo tumor tissue biopsy throughout the study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, and Questionnaire Administration

  • Arm II (nivolumab, ipilimumab)Treatment being tested

    Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes at 1100-1400 on day 1 of each cycle. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance nivolumab for up to a total of 2 years. Patients wear an actigraphy device for 5-7 days at enrollment prior to first infusion and for up to 4 weeks then over 3 weeks starting with visit 4. Patients also undergo check swab and blood sample collection, CT or MRI and MRI or CT of brain throughout the study. Additionally, patients may optionally undergo tumor tissue biopsy throughout the study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, and Questionnaire Administration

  • Arm III (nivolumab, ipilimumab)Existing treatment, for comparison

    Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes at 1400-1700 on day 1 of each cycle. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance nivolumab for up to a total of 2 years. Patients wear an actigraphy device for 5-7 days at enrollment prior to first infusion and for up to 4 weeks then over 3 weeks starting with visit 4. Patients also undergo check swab and blood sample collection, CT or MRI and MRI or CT of brain throughout the study. Additionally, patients may optionally undergo tumor tissue biopsy throughout the study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The TIME Trial - Phase II Randomized Controlled Trial of Time-of-Day Specified Immunotherapy for Advanced Melanoma
Plain-language title
Tests timing of ipilimumab and nivolumab in advanced melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2025